Differential gene expression induced by anti-cancer agent plumbagin is mediated by androgen receptor in prostate cancer cells

Treatment of mice harboring PTEN-P2 tumors in the prostate or on prostate tissue in vivo with 5-hydroxy-2-methyl-1,4-naphthoquinone, also known as plumbagin, results in tumor regression in castrated mice, but not in intact mice. This suggested that dihydrotestosterone (DHT) production in the testes...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 8; no. 1; pp. 2694 - 13
Main Authors Rondeau, Gaelle, Abedinpour, Parisa, Chrastina, Adrian, Pelayo, Jennifer, Borgstrom, Per, Welsh, John
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 09.02.2018
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Treatment of mice harboring PTEN-P2 tumors in the prostate or on prostate tissue in vivo with 5-hydroxy-2-methyl-1,4-naphthoquinone, also known as plumbagin, results in tumor regression in castrated mice, but not in intact mice. This suggested that dihydrotestosterone (DHT) production in the testes may prevent cell death due to plumbagin treatment, but the underlying mechanism is not understood. We performed RNA-seq analysis on cells treated with combinations of plumbagin and DHT, and analyzed differential gene expression, to gain insight into the interactions between androgen and plumbgin. DHT and plumbagin synergize to alter the expression of many genes that are not differentially regulated by either single agent when used alone. These experiments revealed that, for many genes, increases in mRNAs caused by DHT are sharply down-regulated by plumbagin, and that many transcripts change in response to plumbagin in a DHT-dependent manner. This suggests that androgen receptor mediates some of the effects of plumbagin on gene expression.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-018-20451-9